UCB flags new three-year EADV 2026 data showing earlier Bimzelx use improves lesion resolution

UCB said three-year analyses from its EADV 2026 presentation of BIMZELX in moderate-to-severe hidradenitis suppurativa indicate earlier use improves full inflammatory lesion clearance versus later treatment, with stronger tunnel resolution in biologic-naive patients; safety stayed consistent and no new safety signals were reported.